Risk of malignancy and the use of disease-modifying therapy in multiple sclerosis: exploring the role of DMT in a multi-center study
BackgroundThe potential link between disease-modifying therapies (DMTs) and malignancy in multiple sclerosis (MS) patients has generated significant concern, particularly given the immunosuppressive nature of these treatments. Conflicting evidence in the literature has left this issue unresolved, un...
Saved in:
| Main Authors: | Mohammed Bayounis, Mohammed Bin Mahfooz, Mohammed Assiri, Yousef Alghamdi, Fahad Alturki, Mahdi Almutairi, Abdullah Alshelawy, Mohammed Alosaimi, Faisal Almutawa, Abdulrahman Alammar, Yahya Alyahya, Osama Khojah, Seraj Makkawi, Yaser Al Malik |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1492678/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
by: Seraj Makkawi, et al.
Published: (2025-01-01) -
Mitochondrial dysfunction and mitophagy in ADHD: Cellular and molecular mechanisms
by: Mohammed M. Almutairi, et al.
Published: (2024-12-01) -
Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis
by: Abdullah A. Awadh, et al.
Published: (2024-12-01) -
Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience
by: Abdulrahman A. Aljumah, et al.
Published: (2016-01-01) -
Corrigendum to “Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes” [J. Clin. Translat. Endoc. 36C (2024) 100343]
by: Moeber Mohammed Mahzari, et al.
Published: (2024-12-01)